Selenoprotein W controls epidermal growth factor receptor surface expression, activation and degradation via receptor ubiquitination
Cardiovascular outcomes, long-term efficacy and safety In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109]
HF: HR = 0.97, 95% CI 0.811.15, p interaction = 0.11), and the composite of HF hospitalizations and CV death (no HF: HR = 0.80, 95% CI 0.720.89
Collectively, these findings underscore the importance of considering disease heterogeneityincluding hypothyroidism subtype, autoimmune status, metabolic comorbidities, and sex differences-when evaluating ECM remodeling and MAFLD progression
VIP: 1 287
GLP-1 receptor agonists are hydrophilic proteins with molecular weights exceeding 3,000 Daltonsfar above the typical 500 Da threshold for effective passive skin penetration
